191 related articles for article (PubMed ID: 38612786)
21. Preclinical Development of MGC018, a Duocarmycin-based Antibody-drug Conjugate Targeting B7-H3 for Solid Cancer.
Scribner JA; Brown JG; Son T; Chiechi M; Li P; Sharma S; Li H; De Costa A; Li Y; Chen Y; Easton A; Yee-Toy NC; Chen FZ; Gorlatov S; Barat B; Huang L; Wolff CR; Hooley J; Hotaling TE; Gaynutdinov T; Ciccarone V; Tamura J; Koenig S; Moore PA; Bonvini E; Loo D
Mol Cancer Ther; 2020 Nov; 19(11):2235-2244. PubMed ID: 32967924
[TBL] [Abstract][Full Text] [Related]
22. B7-H3/CD276 Inhibitors: Is There Room for the Treatment of Metastatic Non-Small Cell Lung Cancer?
Malapelle U; Parente P; Pepe F; Di Micco MC; Russo A; Clemente C; Graziano P; Rossi A
Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555714
[TBL] [Abstract][Full Text] [Related]
23. A promising target for breast cancer: B7-H3.
Jiang Y; Liu J; Chen L; Qian Z; Zhang Y
BMC Cancer; 2024 Feb; 24(1):182. PubMed ID: 38326735
[TBL] [Abstract][Full Text] [Related]
24. B7-H3 immunoregulatory roles in cancer.
Mortezaee K
Biomed Pharmacother; 2023 Jul; 163():114890. PubMed ID: 37196544
[TBL] [Abstract][Full Text] [Related]
25. New frontiers in immune checkpoint B7-H3 (CD276) research and drug development.
Getu AA; Tigabu A; Zhou M; Lu J; Fodstad Ø; Tan M
Mol Cancer; 2023 Mar; 22(1):43. PubMed ID: 36859240
[TBL] [Abstract][Full Text] [Related]
26. Immune checkpoint B7-H3 protein expression is associated with poor outcome and androgen receptor status in prostate cancer.
Nunes-Xavier CE; Kildal W; Kleppe A; Danielsen HE; Waehre H; Llarena R; Maelandsmo GM; Fodstad Ø; Pulido R; López JI
Prostate; 2021 Sep; 81(12):838-848. PubMed ID: 34125445
[TBL] [Abstract][Full Text] [Related]
27. Immune checkpoint of B7-H3 in cancer: from immunology to clinical immunotherapy.
Zhao B; Li H; Xia Y; Wang Y; Wang Y; Shi Y; Xing H; Qu T; Wang Y; Ma W
J Hematol Oncol; 2022 Oct; 15(1):153. PubMed ID: 36284349
[TBL] [Abstract][Full Text] [Related]
28. B7-H3, a checkpoint molecule, as a target for cancer immunotherapy.
Yang S; Wei W; Zhao Q
Int J Biol Sci; 2020; 16(11):1767-1773. PubMed ID: 32398947
[TBL] [Abstract][Full Text] [Related]
29. B7-H3 contributes to the metastatic capacity of melanoma cells by modulation of known metastasis-associated genes.
Tekle C; Nygren MK; Chen YW; Dybsjord I; Nesland JM; Maelandsmo GM; Fodstad O
Int J Cancer; 2012 May; 130(10):2282-90. PubMed ID: 21671471
[TBL] [Abstract][Full Text] [Related]
30. Expression of B7-H3, a potential factor of tumor immune evasion in combination with the number of regulatory T cells, affects against recurrence-free survival in breast cancer patients.
Maeda N; Yoshimura K; Yamamoto S; Kuramasu A; Inoue M; Suzuki N; Watanabe Y; Maeda Y; Kamei R; Tsunedomi R; Shindo Y; Inui M; Tamada K; Yoshino S; Hazama S; Oka M
Ann Surg Oncol; 2014 Dec; 21 Suppl 4(Suppl 4):S546-54. PubMed ID: 24562936
[TBL] [Abstract][Full Text] [Related]
31. B7-H3 Expression in Merkel Cell Carcinoma-Associated Endothelial Cells Correlates with Locally Aggressive Primary Tumor Features and Increased Vascular Density.
Aung PP; Parra ER; Barua S; Sui D; Ning J; Mino B; Ledesma DA; Curry JL; Nagarajan P; Torres-Cabala CA; Efstathiou E; Hoang AG; Wong MK; Wargo JA; Lazar AJ; Rao A; Prieto VG; Wistuba I; Tetzlaff MT
Clin Cancer Res; 2019 Jun; 25(11):3455-3467. PubMed ID: 30808776
[TBL] [Abstract][Full Text] [Related]
32. Cell-surface antigen profiling of pediatric brain tumors: B7-H3 is consistently expressed and can be targeted via local or systemic CAR T-cell delivery.
Haydar D; Houke H; Chiang J; Yi Z; Odé Z; Caldwell K; Zhu X; Mercer KS; Stripay JL; Shaw TI; Vogel P; DeRenzo C; Baker SJ; Roussel MF; Gottschalk S; Krenciute G
Neuro Oncol; 2021 Jun; 23(6):999-1011. PubMed ID: 33320196
[TBL] [Abstract][Full Text] [Related]
33. B7-H3, a potential therapeutic target, is expressed in diffuse intrinsic pontine glioma.
Zhou Z; Luther N; Ibrahim GM; Hawkins C; Vibhakar R; Handler MH; Souweidane MM
J Neurooncol; 2013 Feb; 111(3):257-64. PubMed ID: 23232807
[TBL] [Abstract][Full Text] [Related]
34. Cytoplasmic expression of B7-H3 and membranous EpCAM expression are associated with higher grade and survival outcomes in patients with clear cell renal cell carcinoma.
Saeednejad Zanjani L; Madjd Z; Axcrona U; Abolhasani M; Rasti A; Asgari M; Fodstad Ø; Andersson Y
Ann Diagn Pathol; 2020 Jun; 46():151483. PubMed ID: 32143173
[TBL] [Abstract][Full Text] [Related]
35. Expression and Clinical Significance of Immune Checkpoint Regulator B7-H3 (CD276) in Human Meningioma.
Deng J; Ma M; Wang D; Zhu H; Hua L; Sun S; Chen H; Cheng H; Qian ZR; Xie Q; Zhang T; Gong Y
World Neurosurg; 2020 Mar; 135():e12-e18. PubMed ID: 31629137
[TBL] [Abstract][Full Text] [Related]
36. B7-H3 expression in colorectal cancer: nuclear localization strongly predicts poor outcome in colon cancer.
Ingebrigtsen VA; Boye K; Tekle C; Nesland JM; Flatmark K; Fodstad O
Int J Cancer; 2012 Dec; 131(11):2528-36. PubMed ID: 22473715
[TBL] [Abstract][Full Text] [Related]
37. A high-content screen of FDA approved drugs to enhance CAR T cell function: ingenol-3-angelate improves B7-H3-CAR T cell activity by upregulating B7-H3 on the target cell surface via PKCα activation.
Lee HW; O'Reilly C; Beckett AN; Currier DG; Chen T; DeRenzo C
J Exp Clin Cancer Res; 2024 Apr; 43(1):97. PubMed ID: 38561833
[TBL] [Abstract][Full Text] [Related]
38. The co-stimulatory molecule B7-H3 promotes the epithelial-mesenchymal transition in colorectal cancer.
Jiang B; Zhang T; Liu F; Sun Z; Shi H; Hua D; Yang C
Oncotarget; 2016 May; 7(22):31755-71. PubMed ID: 27145365
[TBL] [Abstract][Full Text] [Related]
39. B7-H3 Suppresses Antitumor Immunity via the CCL2-CCR2-M2 Macrophage Axis and Contributes to Ovarian Cancer Progression.
Miyamoto T; Murakami R; Hamanishi J; Tanigaki K; Hosoe Y; Mise N; Takamatsu S; Mise Y; Ukita M; Taki M; Yamanoi K; Horikawa N; Abiko K; Yamaguchi K; Baba T; Matsumura N; Mandai M
Cancer Immunol Res; 2022 Jan; 10(1):56-69. PubMed ID: 34799346
[TBL] [Abstract][Full Text] [Related]
40. Pediatric medulloblastoma express immune checkpoint B7-H3.
Li S; Poolen GC; van Vliet LC; Schipper JG; Broekhuizen R; Monnikhof M; Van Hecke W; Vermeulen JF; Bovenschen N
Clin Transl Oncol; 2022 Jun; 24(6):1204-1208. PubMed ID: 34988920
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]